1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Cell & Gene Therapies

Gene Therapy Sponsors Risk Additional Work With Late-Stage Manufacturing Changes

 
• By Derrick Gingery

Commercial scale-up during Phase III trials could create labeling issues and force additional clinical trials, US FDA officials said.

pharmaceutical manufacturing
An OTP official said pre-IND teleconference requests may be converted to written response only because of the agency's growing workload in the space. • Source: Shutterstock

Gene therapy sponsors risk review problems and development delays if they attempt manufacturing changes during pivotal clinical studies.

Commercial production processes should be in place for the entire Phase III trial, said Graeme Price, Gene Therapy Branch 4...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Advanced Technologies